Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00759291 · ClinicalTrials.gov registry record · Phase 2
The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome
A Phase 2 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00759291 is a Phase 2 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 40 participants.
The verdict
NCT00759291, a Phase 2 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
This study will test the hypothesis that reducing the release of free fatty acids (FFA) from fat cells will restore insulin-mediated, endothelium-dependent vasodilation in people with the metabolic syndrome.
Interventions
- DRUG Placebo
- DRUG acipimox
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2006-04-01 |
| Est. Completion | 2017-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00759291
The ClinicalTrials.gov registry entry for NCT00759291 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00759291 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00759291 about?
NCT00759291 is a clinical study titled "The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome". This study will test the hypothesis that reducing the release of free fatty acids (FFA) from fat cells will restore insulin-mediated, endothelium-dependent vasodilation in people with the metabolic syndrome.
What is the current status of trial NCT00759291?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2006-04-01. Estimated completion is 2017-12-30.
What interventions are being tested in trial NCT00759291?
The interventions under investigation include: Placebo (DRUG), acipimox (DRUG).
Who is sponsoring clinical trial NCT00759291?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.